Auxly Cannabis Group Inc. has shared an update on the product strategy of the Company’s wholly-owned subsidiary, Emergence client, Dosecann Inc., as well as a number of strategic additions to the management team of Dosecann.
Dosecann is positioned to play a significant role as a leading research, product development, extraction, formulation and consumer packaged goods manufacturing center in the Canadian cannabis industry, with its 42,000 square foot purpose-built facility in Charlottetown, PEI.
Dosecann has successfully obtained a Dealer’s Licence for Controlled Drugs and Substances from Health Canada and has commenced operations related to the creation of value-added cannabis products, as permitted by the Licence and applicable laws. Dosecann has further subdivided its cannabis activities into two segments, Medical Products and Consumer Packaged Goods.
The Medical Products segment, led by Dr. Christina Woollard and Dr. Bob Chapman, is focused primarily on research and development of new value-added cannabis products for sale to domestic and global medical cannabis and wellness markets.
Part of this segment’s activities will include observational studies and clinical trials to validate the efficacy of new cannabis formulations and intellectual property. It should be noted that, while current regulations do not allow for the creation of Natural Health Products containing cannabis, the Medical Products segment of Dosecann’s business will also focus on addressing market demand for wellness products containing cannabinoids through the research and development of such products within the parameters of applicable legislation.
The Consumer Packaged Goods segment, led by Mr. Peter Crooks and Dr. Bob Chapman, is focused on the creation of novel consumer packaged products for the medical and non-medical cannabis markets. Initially, this segment of Dosecann’s business will be focused on the creation and manufacturing of cannabis edible and cannabis concentrate products for sale within Canada in anticipation of Health Canada permitting the sale of such products in 2019.
The Company is also excited to present Dosecann’s world-class management team as follows:
Greg Boone(Founder & Chief Executive Officer)
Mr. Boone is a seasoned entrepreneur with over 20 years of experience in the Executive Search and Management consulting field through his company HEC GROUP. He specializes in building high performance teams for his clients in the automotive, food, pharma and chemical industries. For the past 5 years, Mr. Boone has applied his talents to the rapidly emerging medical Cannabis industry as an investor and trusted advisor to companies throughout the world looking to enter this space. Mr. Boone founded Dosecann with the primary goal of bringing the best cannabis innovations to domestic and international consumers across medical, wellness and recreational market segments.
Dr. Christina Woollard
(Chief Scientific Officer)
Dr. Woollard has more than 20 years’ experience in the pharmaceutical development industry, across big and small pharma. Prior to joining Dosecann, Dr. Woollard worked as a Formulation Scientist at Pfizer for 4 years and then joined GW Pharmaceuticals, a British biopharmaceutical company. She spent 16 years with GW Pharmaceuticals managing the Product Development team and working on multiple cannabinoid projects including Sativex, Epidiolex, injectables, solid oral dosage forms and THCV products. Dr. Woollard received her degree in Pharmacy from the University of Wales, Cardiff, followed by a PhD, studying the use of liposomes to deliver gene therapy to the lung.
Peter Crooks(Chief of Product Innovation)
Mr. Crooks brings more than 20 years of senior leadership experience in product and brand development across food & beverage, natural health products, medical devices and pharmaceuticals. Most recently as the Executive Director of Canada’s Smartest Kitchen (Canada’s leading food development laboratory) for which Mr. Crooks was recognized in 2017 as one of Atlantic Canada’s Top 50 CEOs, Mr. Crooks successfully led a multi-disciplinary team of chefs, food scientists, marketing professionals and product developers to become Canada’s leading food product development center. In his career, he has overseen the development of over 2,100 products and raised more than $160M to support product innovation and commercialization. He also has been involved in the conceptualization, design and build of three Maritime-based innovation and applied research centers and currently advises several Federal departments on the future of food and innovation.
Dr. Bob Chapman
(Chief Operating Officer)
Dr. Chapman has been applying his broad practical experience in organic and analytical chemistry for the past nineteen years to solve problems of industrial relevance. Most recently, Dr. Chapman was a Principal Research Officer with the National Research Council Canada (“NRC”) Aquatic & Crop Resource Development Research Centre based out of Charlottetown, PEI. With the NRC, Dr. Chapman was responsible for leading a national program and strategic projects focused on the development of Natural Health Products and functional ingredients with private sector companies. In particular, he was responsible for leading strategic projects that aim to develop new functional ingredients based on nutritional oils and plant-based proteins which led to research on cannabinoid-based mixtures. Prior to the NRC, Dr. Chapman spent 6 years working as a Senior Scientist for two venture capital funded bioscience startup companies in San Francisco, California. Dr. Chapman is an Adjunct Professor with the Chemistry Department at the University of Prince Edward Island, the Vice-President of the NHP Research Society, a member of several international standards groups including ASTM D37 committee on cannabis serving as the recording secretary for the processing and handling subcommittee. For NRC ACRD’s research center, he served on national advisory committees supporting the standardization needs for the emerging cannabis industry to ensure quality and safety of cannabis supply. Dr. Chapman is an active member of the Canada’s bioscience community serving on several boards and advisory boards. He holds a Ph.D. in Organic Chemistry from the University of British Columbia, has published widely, holds several patents, and has presented at numerous scientific symposia. Dr. Chapman is the recipient of many awards, including a postdoctoral fellowship from the Natural Sciences and Engineering Research Council of Canada (NSERC) tenured in the Department of Chemistry and Chemical Biology at Harvard University with Professor George Whitesides.
Allan Arsenault(Director of Operations)
Mr. Arsenault has more than 17 years of senior management experience within the food industry. He has extensive experience in GMP, HACCP, budgeting, production planning, human resources, materials management, equipment planning, training, auditing, and facility management. He has experience with CFIA, FDA, and SQF audits and has managed facilities that met and exceeded government food safety standards and has led plants to be industry leaders in food safety. Allan has a business degree in Management and a degree in Socio-economics from UPEI in addition to an engineering certificate from Holland College.
Sandra LeClair
(Director of Quality)
Ms. LeClair has been working within the PEI scientific community for over 20 years, with a wide range of experience in multiple roles in academia, government, and private industry. For the past 6 years, she managed the Quality Control department in a GMP facility manufacturing animal vaccines that were distributed worldwide. Prior to this, Ms. LeClair spent 5 years as a Senior Scientist for a global animal health company, working on developing new and unique animal health products. Ms. LeClair graduated with honors from UNB with a Bachelor of Science, and proceeded to enroll in the Masters of Science program at UPEI, completing her Master’s thesis in 2000.
Jeremy Stiles
(Regulatory Affairs/GMP Consultant)
Mr. Stiles is an experienced quality professional in the pharmaceutical and life sciences industry. With over 30 years’ experience as a leader in the public and private sector he has worked extensively to design, develop and implement quality and environmental management systems. He is well versed in a variety of quality assurance standards and the regulatory requirements associated with pharmaceutical filings such as CMC, DMF’s, NDA’s or ANDA’s. Prior to joining Dosecann, Mr. Stiles spent 20 years with BioVectra, most recently as Director, Quality Assurance and Regulatory Affairs. Mr. Stiles graduated from the University of London England with a Masters of Science in Environmental Management.
“On behalf of the Board of Directors and Management, it gives me great pleasure to congratulate Greg on building a world-class operation and to welcome the incredible team he has assembled at Dosecann to the Auxly Cannabis platform“.
Hugo Alves, President of Auxly
“Dosecann is the cornerstone asset in the midstream segment of our business and we feel strongly that the team that has been assembled and the product innovation and development strategy that Dosecann has developed distinguishes Auxly from its peers and puts us in a position to become one of the leading cannabis products companies in the world. We are hugely excited to see these products come to life at Dosecann and offering consumers innovative quality products backed by research and science!”
Hugo Alves, President of Auxly
About Auxly Cannabis Group Inc. (TSX.V: XLY)
Auxly Cannabis Group is a collective of entrepreneurs with a passion for the cannabis industry past, present and future. Our mandate is to facilitate growth for our partners by providing them with financial support and sharing our collective industry experience. Our partners all have different visions, voices and brand values, and all share a common goal—to build a world-class industry based on ethics, diversity, quality and innovation.
About Dosecann
Dosecann is a Canadian Licensed Dealer dedicated to developing cannabis solutions for the cannabis industry. Located in Charlottetown, PEI, Dosecann’s purpose-built, 42,000 square foot facility will be the hub for cannabis extraction, quality testing, research and development, product formulation and manufacturing.